

艾迪注射液联合化疗治疗进展期胃癌的Meta分析

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年02期 页码: 281-286 栏目: 论著 (消化·泌尿系肿瘤) 出版日期: 2018-12-08

Title: Meta-analysis of Aidi injection combined with chemotherapy for advanced gastric cancer

作者: 李梦丽¹; 汪红红²; 霍礼超³; 刘满想¹; 周永宁⁴; 关泉林¹

1.兰州大学第一医院肿瘤科; 3.老年病科; 4.消化科,甘肃 兰州 730000;2.甘肃省岷县人民医院心血管科,甘肃 兰州 730000

Author(s): Li Mengli¹; Wang Honghong²; Huo Lichao³; Liu Manxiang¹; Zhou Yongning⁴; Guan Quanlin¹

1. Department of Oncology; 3. Department of Geriatrics; 4. Department of Gastroenterology, The First Hospital of Lanzhou University, Gansu Lanzhou 730000, China; 2. Department of Cardiovascular Medicine, Minion People's Hospital of Gansu Province, Gansu Lanzhou 730000, China.

关键词: 艾迪注射液; 替吉奥胶囊; 奥沙利铂注射液; 晚期胃癌

Keywords: Aidi injection; Oxaliplatin; advanced gastric cancer

分类号: R735.2

DOI: 10.3969/j.issn.1672-4992.2019.02.025

文献标识码: A

摘要: 目的:评估替吉奥胶囊与奥沙利铂注射液联合艾迪注射液治疗进展期胃癌的疗效及安全性。方法:检索PubMed、The Cochrane library、Web of Science、EMBASE、中国生物医学文献服务系统、中国知网、维普、万方等8个数据库。收集关于替吉奥胶囊与奥沙利铂注射液联合艾迪注射液治疗进展期胃癌的随机对照试验(RCTs)。提取资料并且评价文献质量。采用Rev Man5.3软件进行统计分析。结果:两组有效率相比,差异有统计学意义 [OR=1.60, 95%CI=(1.08, 2.37), P=0.02]。实验组白细胞减少 [OR=0.36, 95%CI=(0.23, 0.55), P < 0.000 01]、血红蛋白减少 [OR=0.45, 95%CI=(0.21, 0.96), P=0.04]、血小板减少 [OR=0.49, 95%CI=(0.29, 0.81), P=0.006]、恶心呕吐 [OR=0.45, 95%CI=(0.31, 0.68), P < 0.000 1]、腹泻 [OR=0.46, 95%CI=(0.26, 0.83), P=0.01]、周围神经毒性 [OR=0.32, 95%CI=(0.18, 0.56), P < 0.000 1]、肝功能异常 [OR=0.26, 95%CI=(0.12, 0.57), P=0.000 7]发生率均低于对照组,差异有统计学意义。结论:艾迪注射液联合替吉奥胶囊与奥沙利铂注射液治疗进展期胃癌可以提高治疗效果,减少不良反应的发生。

Abstract: Objective: To evaluate the effectiveness and safety of S-1 and Oxaliplatin combined with Aidi injection for advanced gastric cancer. Methods: retrieval from PubMed, The Cochrane library, Web of Science, EMBASE, China Biology Medicine, China National Knowledge Infrastructure, VIP, Wanfang), randomized controlled trial about S-1 and Oxaliplatin combined with Aidi Injection for advanced gastric cancer were collected. Meta-analysis was conducted by Rev Man5.3 software after data extraction and quality evaluation. Results: There was statistical significance in effective rate of gastric cancer between 2 groups [OR=1.60, 95%CI=(1.08, 2.37), P=0.02]. The incidence of leukopenia [OR=0.36, 95%CI=(0.23, 0.55), P < 0.000 01], hemoglobin reduction [OR=0.45, 95%CI=(0.21, 0.96), P=0.04], thrombocytopenia [OR=0.49, 95%CI=(0.29, 0.81), P=0.006], nausea and vomiting [OR=0.45, 95%CI=(0.31, 0.68), P < 0.000 1], diarrhea [OR=0.46, 95%CI=(0.26, 0.83), P=0.01], peripheral nerve toxicity [OR=0.32, 95%CI=(0.18, 0.56), P < 0.000 1], abnormal liver function [OR=0.26, 95%CI=(0.12, 0.57), P=0.000 7] in trial group were lower than control group, with statistical significance. Conclusion: S-1 and Oxaliplatin combined with Aidi Injection for advanced gastric cancer can improve therapeutic efficacy and reduce the occurrence of adverse drug reaction.

参考文献/REFERENCES

- [1] Niu L, Liang SH, Wu KC. Progress in endoscopic diagnosis of early gastric cancer [J]. Gastroenterology, 2016, 21(12):752-754. [牛璐, 梁树辉, 吴开春. 早期胃癌的内镜诊断进展 [J]. 胃肠病学, 2016, 21(12):752-754.]
- [2] Sun K, Chen S, Ye J, et al. Endoscopic resection versus surgery for early gastric cancer: A systematic review

- and meta-analysis [J]. *Digestive Endoscopy*, 2016, 28(5):513-525.
- [3] Mohammad NH, Ter Veer E, Ngai L, et al. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: Triplet versus doublet chemotherapy: A systematic literature review and Meta-analysis [J]. *Cancer Metastasis Reviews*, 2015, 34(3):429-441.
- [4] Luo HQ, He YF. Progress in molecular targeted therapy for advanced gastric cancer [J]. *Chinese Clinical Oncology*, 2017, 22(5):455-460. [罗会芹,何义富.晚期胃癌分子靶向治疗进展 [J].*临床肿瘤学杂志*, 2017, 22(5):455-460.]
- [5] Jiancheng W, Long G, Ye Z, et al. Effect of Aidi injection plus chemotherapy on gastric carcinoma: a Meta-analysis of randomized controlled trials [J]. *Journal of Traditional Chinese Medicine*, 2015, 35(4):361-374.
- [6] Zhang XP. The task and challenge of tumor imaging from the development of evaluation criteria of solid tumor efficacy [J]. *Chinese Journal of Radiology*, 2010, 44(4):341-342. [张晓鹏.从实体瘤疗效评价标准发展看肿瘤影像学的任务与挑战 [J].*中华放射学杂志*, 2010, 44(4):341-342.]
- [7] Sun Y. Chinese Internal medicine oncology: Advance in exploration [J]. *Journal of Medical Research*, 2012, 41(4):1. [孙燕.中国内科肿瘤学:在探索中前行 [J].*医学研究杂志*, 2012, 41(4):1.]
- [8] Fan CM, Ge CH, Lu F, et al. Efficacy of Aidi injection combined with S-1 and oxaliplatin in the treatment of advanced gastric cancer [J]. *Modern Journal of Integrated Traditional and Western Medicine*, 2011, 20(36):4607-4609. [范成美, 葛成华, 陆锋, 等.艾迪注射液联合S-1、奥沙利铂治疗晚期胃癌的疗效分析 [J].*现代中西医结合杂志*, 2011, 20(36):4607-4609.]
- [9] Li YQ, Xiong HL, Yuan X. Clinical observation of 30 cases of advanced gastric cancer treated with Aidi injection combined with oxaliplatin injection and ticaocapsules [J]. *Journal of New Chinese Medicine*, 2013, 45(8):136-138. [李轶群, 熊海林, 袁霞.艾迪注射液联合奥沙利铂注射液与替吉奥胶囊治疗晚期胃癌30例临床观察 [J].*新中医*, 2013, 45(8):136-138.]
- [10] Liu HZ, Wang TF, Han DH, et al. Application of SOX and Aidi injection in adjuvant chemotherapy for advanced gastric cancer after surgery [J]. *Zhejiang Journal of Integrated Traditional Chinese and Western Medicine*, 2012, 22(6):447-448. [刘海忠, 王天飞, 韩东海, 等. SOX方案联合艾迪注射液在进展期胃癌术后辅助化疗中的应用 [J].*浙江中西医结合杂志*, 2012, 22(6):447-448.]
- [11] Wang J. Application of SOX and Aidi injection in postoperative adjuvant chemotherapy for advanced gastric cancer [J]. *China Modern Medicine*, 2013, 20(21):66-67. [王坚. SOX方案联合艾迪注射液在进展期胃癌术后辅助化疗中的应用 [J].*中国当代医药*, 2013, 20(21):66-67.]
- [12] Xu JL, Lu WM. Effects of Aidi injection combined with SOX chemotherapy on the survival period and clinical benefit of patients with advanced gastric cancer [J]. *Journal of Chinese Medicinal Materials*, 2017, 40(5):1221-1224. [徐建林, 陆为民.艾迪注射液联合SOX方案化疗对中晚期胃癌患者生存期及临床受益的影响 [J].*中药材*, 2017, 40(5):1221-1224.]
- [13] Zheng Y. Clinical observation of Aidi injection combined with chemotherapy in treating gastric cancer [J]. *Journal of Basic and Clinical Oncology*, 2016, 29(6):496-497. [郑羽.艾迪注射液联合化疗治疗胃癌的临床观察 [J].*肿瘤基础与临床*, 2016, 29(6):496-497.]
- [14] Wang YL. The clinical effect of Aidi injection combined with chemotherapy for advanced gastric cancer [J]. *China Modern Medicine*, 2016, 23(11):51-53. [王永领.艾迪注射液联合化疗方案治疗晚期胃癌的临床效果 [J].*中国当代医药*, 2016, 23(11):51-53.]
- [15] Xiao LL. Clinical study of traditional Chinese medicine combined with chemotherapy for advanced gastric cancer [D]. Xinjiang Medical University, 2013. [肖亮亮.中药配合化疗治疗中晚期胃癌的临床研究 [D].新疆医科大学, 2013.]
- [16] Chi ZH. A Meta-analysis of the treatment of advanced gastric cancer by Aidi injection [J]. *China Pharmacy*, 2017, 28(33):4675-4678. [迟志恒.替吉奥联合艾迪注射液治疗晚期胃癌的Meta分析 [J].*中国药房*, 2017, 28(33):4675-4678.]
- [17] Fu L. Treatment of advanced gastric cancer by Aidi injection with oxaliplatin, fluorouracil and calcium folic acid [J]. *Journal of Medical Forum*, 2018, 39(1):129-131. [付琳.艾迪注射液辅助奥沙利铂、氟尿嘧啶、亚叶酸钙治疗晚期胃癌疗效观察 [J].*医药论坛杂志*, 2018, 39(1):129-131.]
- [18] Xu J, Ju WZ, Tan HS. Overview of pharmacological action and clinical application of Aidi injection [J]. *Pharmaceutical and Clinical Research*, 2012, 20(1):48-52. [徐洁, 居文政, 谈恒山.艾迪注射液药理作用及临床应用研究概况 [J].*药学与临床研究*, 2012, 20(1):48-52.]

备注/Memo: 国家重点研发计划(编号: 2017YFC0908300)

更新日期/Last Update: 1900-01-01